BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gane E, Stedman C, Dole K, Chen J, Meyers CD, Wiedmann B, Zhang J, Raman P, Colvin RA. A Diacylglycerol Transferase 1 Inhibitor Is a Potent Hepatitis C Antiviral in Vitro but Not in Patients in a Randomized Clinical Trial. ACS Infect Dis 2017;3:144-51. [PMID: 27788579 DOI: 10.1021/acsinfecdis.6b00138] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Kim D, Goo JI, Kim MI, Lee SJ, Choi M, Than TT, Nguyen PH, Windisch MP, Lee K, Choi Y, Lee C. Suppression of Hepatitis C Virus Genome Replication and Particle Production by a Novel Diacylglycerol Acyltransferases Inhibitor. Molecules 2018;23:E2083. [PMID: 30127285 DOI: 10.3390/molecules23082083] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Koul S, Kurhade S, Bhosale S, Naik K, Salunkhe V, Ravula S, Punde P, Velayutham R, Tiwari A, Ahl D, Malkapuram S, Mudagala V, Raje A, Umrani D, Tambe S, Patil P, Singh U, Bhuniya D, Hariharan N, Mookhtiar K. Design and synthesis of novel spirocyclic carboxylic acids as potent and orally bioavailable DGAT1 inhibitors and their biological evaluation. Bioorg Med Chem Lett 2022;62:128632. [PMID: 35189320 DOI: 10.1016/j.bmcl.2022.128632] [Reference Citation Analysis]
3 Crouchet E, Wrensch F, Schuster C, Zeisel MB, Baumert TF. Host-targeting therapies for hepatitis C virus infection: current developments and future applications. Therap Adv Gastroenterol 2018;11:1756284818759483. [PMID: 29619090 DOI: 10.1177/1756284818759483] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
4 Ji X, Li Z. Medicinal chemistry strategies toward host targeting antiviral agents. Med Res Rev 2020;40:1519-57. [PMID: 32060956 DOI: 10.1002/med.21664] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]